Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CASP2 | P42575 | 1/20 | 0.35 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.34 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.34 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.33 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.33 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.33 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.33 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.33 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13124556 | 0.95 | MEN1 (0.59) | MEN1KMT2ARECQLALDH1A1SMN1; SMN2 | |
| SCHEMBL25968884 | 0.95 | MEN1 (0.59) | MEN1KMT2ARECQLALDH1A1SMN1; SMN2 | |
| SCHEMBL25968834 | 0.89 | MEN1 (0.48) | MEN1KMT2ARECQLALDH1A1 | |
| SCHEMBL24641589 | 0.86 | SMN1; SMN2 (0.37) | MEN1KMT2AALDH1A1SMN1; SMN2KISS1R | |
| SCHEMBL21964562 | 0.86 | ALDH1A1 (0.44) | MEN1KMT2AALDH1A1SMN1; SMN2CASP2 | |
| SCHEMBL17128632 | 0.84 | KISS1R (0.38) | MEN1KMT2AALDH1A1SMN1; SMN2CASP2 | |
| SCHEMBL24372267 | 0.83 | MEN1 (0.57) | MEN1KMT2ARECQLCASP2SIRT6 | |
| SCHEMBL23772060 | 0.83 | MEN1 (0.57) | MEN1KMT2ARECQLCASP2SIRT6 | |
| SCHEMBL18412629 | 0.82 | ALDH1A1 (0.55) | MEN1KMT2AALDH1A1SMN1; SMN2CASP2 | |
| SCHEMBL16174166 | 0.81 | CASP2 (0.56) | MEN1KMT2ACASP2TSHRFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150175665-A1 | ANALOGUES OF GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE (GIP) MODIFIED AT N-TERMINAL | IPSEN PHARMA S.A.S. (FR) | 2015-06-25 | — | — | US | disclosed |
| US-8999940-B2 | Analogues of glucose-dependent insulinotropic polypeptide (GIP) modified at N-terminal | IPSEN PHARMA S.A.S. (FR) | 2015-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175665-A1 | ANALOGUES OF GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE (GIP) MODIFIED AT N-TERMINAL | GIPR, GPR119, GLP1R | MEN1 1086/4885KMT2A 3970/4885RECQL 4831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.